As a targeted JAK1 inhibitor, and given its success in RA, Upadacitinib may represent an interesting therapeutic option for the inhibition of the STAT3 pathway in refractory LGLL patients [24,59]. Here, STAT3 is linked to rheumatoid arthritis.